Steven J. Swanson - Concepedia

Author

Steven J. Swanson

Also Known As

E. Tomanio, S J Swanson, S Swanson, S. J. Swanson, S. Swanson, Steve J. Swanson, Steve Swanson, Steven J Swanson, Steven J. Swanson, Steven James Swanson

120

Publications

4.3K

Citations

H-Index

129

Concepts

All Affiliations

Amgen (United States)The Ohio State University Janssen (United States)Bristol-Myers Squibb (United States)United States Food and Drug Administration

About

Steven J. Swanson is an author at Amgen (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	34	2.6K
2	Allergy	12	12	768
3	Engineering	7	7	266
4	Natural Sciences	4	4	246
5	Public Health	1	1	45

Steven J. Swanson

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products Anthony R. Mire‐Sluis, Yu Chen Barrett, Viswanath Devanarayan, Journal of Immunological Methods VaccinationBiotechnology ProductsBioanalysisImmunologyBiotechnology	2004	609
Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations Ganesh M. Shankar, Steven Arkin, Laurent Cocea, The AAPS Journal ImmunohematologyPeptides—harmonized TerminologyTactical RecommendationsAllergyImmunodeficiencies	2014	323
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen Aaron K. Patton, Michael C. Mullenix, Steven J. Swanson, Journal of Immunological Methods Immunocytochemical TechniqueBiochemistryNatural SciencesBioanalysisImmunology	2005	198
Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab James A. Lofgren, Sripriya Dhandapani, Jason Pennucci, The Journal of Immunology	2007	191
A Phase I Study of Adenovirus-Mediated Wild-Type <i>p53</i> Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer Martin Schüler, Christoph Rochlitz, Jo Ann Horowitz, Human Gene Therapy Wild-type P53Gene TherapiesCancer-associated VirusMedicineExpression Vector	1998	164
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Eugen Koren, Anne S. De Groot, Vibha Jawa, Clinical Immunology ImmunodeficienciesImmunologyPathologyImmunochemistryClinical Validation	2007	141
Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report Krys J. Miller, Ronald R. Bowsher, Abbie Celniker, Pharmaceutical Research	2001	112
Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin Steven J. Swanson, John Ferbas, Patrick Mayeux, Nephron Clinical Practice	2004	93
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics Danika Wullner, Lei Zhou, Erica Bramhall, Clinical Immunology Cancer ImmunosurveillanceAutoimmune DiseaseAllergyVitro PbmcT-regulatory Cell	2010	83
Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal Antibodies Michael Moxness, Suzanna Tatarewicz, Dohan Weeraratne, Clinical Chemistry ImmunohematologyImmunologyImmunophenotypingDrug CompoundsRuthenium-conjugated Drug Compounds	2005	80

Page 1